✨ Free AI Report
Cell Source, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Cell Source, Inc.
Company Research

Cell Source, Inc.: Business Overview, Financials & Competitive Analysis

Cell Source Inc., founded in 2012, is a biotechnology firm concentrating on the development of cell therapy treatments for immunotherapy. Its lead product is the Veto Cell immune system management technology, which is...

Analyst-debate audio for Cell Source, Inc.

AskCyborg analysts argue the bull and bear cases for Cell Source, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
3/ 10Challenged

Cyborg Score thesis

Veto Cell immune tolerance platform has potential to address major unmet needs in transplantation and cell therapy, but...

Read the full analyst-debate transcript →
Industry Stem Cell Therapy
6 named competitors
2 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 28, 2026
AI-Verified Research
30+ Page Report

Get the Latest Cell Source, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Cell Source, Inc. Overview

Pro stress-test →

Cell Source Inc., founded in 2012, is a biotechnology firm concentrating on the development of cell therapy treatments for immunotherapy. Its lead product is the Veto Cell immune system management technology, which is an immune tolerance biotechnology that enables the selective blocking of immune responses. The company targets blood cancers, organ transplantation, genetic blood disorders, and autoimmune diseases.

Strategic Profile

Pro stress-test →

Cell Source's work revolves around its proprietary Veto Cell technology, an immune tolerance platform designed to selectively block adverse immune responses. The company is developing and evaluating its Veto Cell CAR-T platform for allogeneic CAR-T settings, and its Veto Cell technologies are also being developed to facilitate safe, mismatched organ transplants without the need for life-long immune system suppression medications. As a public micro-cap trading OTC, the company faces capital constraints typical of early-stage cell therapy developers.

Competitive Landscape

Pro stress-test →

Cell Source competes in the cell therapy and immunotherapy space against larger, better-capitalized biotech firms. Direct competitors include Juno Therapeutics and Kite Pharma (now Gilead), both with established CAR-T platforms and significantly larger market caps. The company also competes indirectly with transplant immunology and organ preservation specialists. Cell Source's immune tolerance focus is differentiated, but capital and operational constraints limit competitive reach versus well-funded rivals.

Industry Context

Cell Source, Inc. operates in Stem Cell Therapy.

Key facts

Founded: 2012 · Headquarters: New York, NY, USA · Employees: ~1 · Revenue: Estimated $0-2M (pre-revenue or minimal; company is preclinical/early-stage) · Market cap: $56.4M

What the analysts stress-tested

The top findings that survived the multi-agent debate for Cell Source, Inc..

  • Market cap ~$56M as of October 2026 with minimal reported employees suggests severe undercapitalization relative to biotechnology development timelines; cash runway and financing capacity present material survival risk.
  • Proprietary Veto Cell platform addresses selective immune tolerance—a fundamental immunology challenge affecting transplant rejection and CAR-T therapy; technology roadmap includes CAR-T and organ transplantation programs.

Recent developments

Material events tracked by the AskCyborg corpus.

  • July 2022Board director resignations (Ben Friedman and David Zolty) with no material disagreement noted
  • March 2021USPTO issued new patents for Veto Cell technology platform
Get alerted when Cell Source, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Fate TherapeuticsEngineered cell therapies including CAR-T and iPSC-derived products→Atara BiotherapeuticsAllogeneic T-cell therapies for blood cancers and viral infections→Bellicum PharmaceuticalsT-cell therapy platform for hematologic malignancies and immunotherapy→Celyad OncologyCAR-T cell therapy developer for cancer immunotherapy→Mustang BioCell therapy platform for hematologic malignancies and solid tumors→Vor BiopharmaCell therapy company developing engineered hematopoietic stem cell therapies→

Compare Cell Source, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Cell Source, Inc. operates in Stem Cell Therapy. See how the rest of the sector scores on the Cyborg framework.

Browse Stem Cell Therapy research →
NEW · MCP server

Ask your AI assistant about Cell Source, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Cell Source, Inc. and its top competitor on Cyborg Score”
“What did Cell Source, Inc. do this quarter?”
“Is Cell Source, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Cell Source, Inc. do?+
Cell Source Inc., founded in 2012, is a biotechnology firm concentrating on the development of cell therapy treatments for immunotherapy. Its lead product is the Veto Cell immune system management technology, which is...
What is Cell Source, Inc.'s Cyborg Score?+
Cell Source, Inc. has a Cyborg Score of 3/10 (Challenged). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Cell Source, Inc.'s main competitors?+
Named competitors include Fate Therapeutics, Atara Biotherapeutics, Bellicum Pharmaceuticals, Celyad Oncology. The full competitive landscape is in the AskCyborg report.
How can I get the full Cell Source, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Cell Source, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Cell Source, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.